-
Phase 2b Trial of MS1819 Will Be Conducted at TDN Clinical Sites
AzurRx BioPharma has been cleared to conduct its Phase 2b OPTION 2 trial evaluating MS1819 at Therapeutics Development Network (TDN) clinical sites. Read the rest of the story here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.